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ABSTRACT
Genomic analysis of ovarian cancer cell lines has revealed a panel that best 
represents the most common ovarian cancer subtype, high-grade serous ovarian 
cancer (HGSOC). However, these HGSOC-like cell lines have not been extensively 
applied by ovarian cancer researchers to date, and the most commonly used cell 
lines in the ovarian cancer field do not genetically resemble the major clinical type 
of the disease. For the HGSOC-like lines to serve as suitable models, they need 
to be characterized for common functional assays.  To achieve that objective, we 
systematically studied a panel of HGSOC cells CAOV3, COV362, Kuramochi, OVCAR4, 
OVCAR5, OVCAR8, OVSAHO and SNU119 for migration, invasion, proliferation, 
clonogenicity, EMT phenotype and cisplatin resistance. They exhibited a range of 
efficacies and OVCAR5, OVCAR8 and Kuramochi were the most aggressive. SNU119 
and OVSAHO cells demonstrated the lowest functional activities. Wide differences 
in expression of EMT markers were observed between cell lines. SNU119 were the 
most epithelial and OVCAR8 had the most mesenchymal phenotype. COV362 was 
the most resistant to cisplatin while CAOV3 was the most sensitive. Taken together, 
our systematic characterization represents a valuable resource to help guide the 
application of HGSOC cells by the cancer research community.
INTRODUCTION
Ovarian cancer (OC) is the most lethal gynecological 
malignancy and is the 5th leading cause of cancer related 
deaths among women in the United States of America [1]. 
While many cancers have witnessed significant decrease 
in mortality in recent years due to advances in early 
detection and improved treatment options, OC death rates 
have remained relatively constant, with a 5-year survival 
rate under 30% for the past 40 years [2–4]. Discovery of 
effective therapeutics has been hampered by the lack of 
similarity between experimental models and real disease. 
Better models are needed if laboratory results are to be 
efficiently translated to patients [5, 6].
Until recently, a major issue with identifying good 
experimental models has been a lack of knowledge 
regarding the molecular and mutational profiles that are 
most characteristic of OC [6]. High-grade serous ovarian 
cancer (HGSOC) represents approximately 80% of OC [7] 
and contributes to two-thirds of all OC deaths [6], making 
it the most common as well as the most lethal subtype. 
Therefore, experimental models closely representing 
HGSOC are highly desirable.
The Cancer Genome Atlas Research Network 
(TCGA) study [8] revealed recurring genetic and 
molecular changes present in 489 clinically annotated 
stage-II–IV HGSOC tumors.  Key recurring features of 
HGSOC included mutation of TP53 (~96% of tumors), 
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loss of function or methylation in BRCA1/2, increased 
copy number variation, and statistically significant 
occurrence of somatic mutations in nine genes including 
NF1, RB1, and CDK12. The study also identifies a 
number of signaling pathways commonly altered in 
HGSOC, including the FOXM1 signaling pathway.  A 
subsequent study [6] compared 47 cell line molecular 
profiles to the TCGA data and suggested that the most 
highly cited cell lines in research papers investigating 
HGSOC are not the cell lines most likely to actually 
represent HGSOC.  Specifically, out of 47 cell lines used 
in the analysis, the two most highly cited - SKOV3 and 
A2780 - had some of the lowest suitability scores for 
HGSOC and were therefore ranked as “unlikely high 
grade serous.” A number of the cell lines listed as “likely 
high-grade serous” in this study have had this status 
confirmed in other studies using a variety of metrics 
[5, 7, 9]. Angleiso et al. reported a set of molecular 
features and biomarkers in a panel of ovarian cancer cells 
establishing their histotype [5]. A subsequent study by 
Beaufort et al. with a panel of ovarian cancer cell lines 
showed the cellular morphology correlated with specific 
biological and molecular characteristics [7]. Moreover, 
HGSOC cells like Kuramochi and OVSAHO were found 
to have significantly reduced capacity to form xenograft 
tumors as compared to SKOV3 cells [10].
The realization that the most commonly used cell 
lines in OC research are not representative of HGSOC will 
steadily lead to a shift towards using the more HGSOC-
like cell lines. In order to be useful, these HGSOC cell 
lines need to be well characterized and should accurately 
represent the disease [4]. Since many of them are not well 
reported in literature, it is necessary to better understand 
their functional characteristics in order to widely apply 
them in OC research. 
Recent studies have implicated EMT as a driver 
of OC metastasis [11–13]. An assessment of the basal 
expression of genes related to the EMT signature of 
different ovarian carcinoma cell lines would be key in 
understanding their metastatic potential. Additionally, 
since platinum is widely used as a first line of treatment 
in OC, knowledge of the response of these HGSOC cells 
to platinum would be very useful for researchers studying 
drug resistance or combination therapies. 
We report the characterization of a panel of these 
HGSOC cell lines for commonly used in vitro functional 
assays, their sensitivity to cisplatin and their expression 
of epithelial and mesenchymal markers. The absence 
of published reports of such consolidated data hampers 
effective transition to the use of these HGSOC cell line 
models for ovarian cancer research. We believe that our 
data will be very beneficial to the field and will serve as 
a guide to optimize assay and treatment conditions for 
various mechanistic, drug development and screening 
studies. It will enable researchers to extensively use these 
to more accurately model OC.
RESULTS
The ability of the HGSOC cell lines CAOV3, 
COV362, Kuramochi, OVCAR4, OVCAR5, OVCAR8, 
OVSAHO and SNU119 to migrate, invade, proliferate 
and form colonies was investigated. HeyA8 cells 
were also included in the set, as they have been very 
well characterized in all the four assays and serve as a 
control. Preliminary experiments were first conducted to 
identify the experimental conditions that were conducive 
to comparison of assay results between the cell lines. 
The final conditions used for migration, invasion, 
colony formation and proliferation assays for each cell 
line are listed in Table 1. The ability of cancer cells to 
respond to localized gradients of chemoattractants is 
considered crucial for metastasis [14]. Migration assays 
are extensively used in vitro to study the role of genes 
or effect of treatments on metastasis [15]. Transwell 
migration assays were conducted to compare the ability 
of the cell lines to move towards a chemoattractant 
(growth medium with 10% serum). The number of cells 
migrated per field was counted and data from the three 
independent experiments with each cell line is presented 
in Supplementary Figure 1 and the mean values for all 
cell lines are plotted together in Figure 1. OVCAR5 and 
OVCAR4 cells had the maximum number of migrated 
cells per field while OVSAHO and SNU119 had the least 
(Figure 1). There were significant differences in the means 
across cell lines (p < 0.0001). OVCAR5 and OVCAR4 
were not different from each other but were different 
from all other cell lines. OVCAR8, CAOV3, COV362, 
and HeyA8 were not different from each other (with the 
exception of HeyA8 being different from OVCAR8), but 
were different from all other cell lines.  Kuramochi was 
significantly different from all other cell lines. SNU119 
and OVSAHO were not different from each other but were 
significantly different from all other cell lines. Since each 
cell line had a different propensity to migrate, the number 
of cells seeded per insert had to be varied between cell 
lines in order to obtain quantifiable migrated cell numbers. 
The migration was then normalized to the number of 
cells seeded and ranked accordingly (Table 2). Based on 
this, HeyA8 cells were found to have the greatest ability 
to migrate followed by OVCAR5 and OVCAR4 while 
OVSAHO and SNU119 remained the least migratory 
cells (Table 2). The cell sizes ranged between 15.78 μm to 
20.31 μm (Supplementary Table 1).
In addition to the ability to migrate towards 
chemoattractants, cancer cells need to have the ability 
to invade through the extracellular matrix surrounding 
cells and the basement membrane. Therefore, the ability 
of these cells to invade through matrigel was studied by 
using transwell invasion assay [16, 17]. The OC cells 
were allowed to invade through matrigel coated transwell 
inserts for 16 h. HeyA8 and OVCAR5 cells were found 
to be the most invasive while OVSAHO and SNU119 
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did not invade at all (Figure 2). There were significant 
differences in the means across cell lines (p < 0.0001). 
OVCAR5 and HeyA8 were not different from each other 
but were different from all other cell lines. OVCAR8 was 
different from all other cell lines, Kuramochi was not 
different from OVCAR4 but was different from all other 
cell lines. OVCAR4, COV362, and CAOV3 were not 
different but were different from all other cell lines. The 
independent experiments with each cell line are presented 
in Supplementary Figure 2. Normalizing the invasion to 
the number of cells seeded again resulted in HeyA8 cells 
as the most invasive followed by OVCAR5 (Table 2).
Having studied the ability of the OC cells to 
migrate and invade in response to chemoattractants, we 
proceeded to test their proliferation and clonogenicity. 
Both these traits are essential for tumor progression and 
are extensively used to study the effects of therapies, 
role of specific regulators or genes in OC [18, 19]. For 
proliferation, 1000, 2000, 5000 or 10,000 OC cells 
were seeded/well in 96-well plates and allowed to grow 
for 5 days. Proliferation was measured using the 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) assay, which is one of the most commonly used 
and economical assays to measure cell growth. The cell 
lines had varying rates of proliferation (Supplementary 
Figure 3) and only the experiment with 2000 cells seeded 
per well was found to be optimal for comparing the whole 
panel of cells (Figure 3). Once again, HeyA8 cells were 
found to be the most proliferative followed by OVCAR5 
and OVCAR8. Kuramochi, OVCAR4 and SNU119 were 
found to be the least proliferative (Figure 3). There were 
significant differences in the means across cell lines 
(p < 0.0001). HeyA8 was different from all other cell 
lines. OVCAR5, OVCAR8 and CAOV3 were not different 
from each other but different from all other cell lines. 
COV362, Kuramochi, OVCAR4 and SNU119 were not 
different from each other (with the exception of COV362 
being different from SNU119) but were different from all 
other cell lines.
To study the clonogenicity of the cell lines, colony 
formation assay was conducted by seeding 1000 cells/well 
of a 6-well plate and the resulting colonies were fixed, 
stained, imaged and counted. OVCAR8 formed the most 
colonies while OVSAHO formed the least (Figure 4). 
There were significant differences in the means across 
cell lines (p < 0.0001). Both OVCAR8 and OVSAHO 
Table 1: Functional assay conditions
Cell Line
Invasion/
Migration 
Cell #
Migration 
Time
Invasion 
Time
Colony 
formation 
Cell #
Colony 
Formation 
Time
MTT Cell #
MTT 
Incubation 
Time
MTT 
Growth 
Time
CAOV3 200,000 cells 8 hrs 16 hrs 1,000 cells 22 days 10k, 5k, 2k, 1k 4 hrs 4 days
COV362 200,000 cells 8 hrs 16 hrs 1,000 cells 17 days 10k, 5k, 2k, 1k 4 hrs 4 days
HeyA8 50,000 cells 3 hrs 16 hrs 1,000 cells 7 days 10k, 5k, 2k, 1k 1.5 hrs 4 days
Kuramochi 200,000 cells 8 hrs 16 hrs 1,000 cells 14 days 10k, 5k, 2k, 1k 4 hrs 4 days
OVCAR4 200,000 cells 8 hrs 16 hrs 1,000 cells 14 days 10k, 5k, 2k, 1k 4 hrs 4 days
OVCAR5 200,000 cells 8 hrs 16 hrs 1,000 cells 14 days 10k, 5k, 2k, 1k 4 hrs 4 days
OVCAR8 200,000 cells 8 hrs 16 hrs 1,000 cells 14 days 10k, 5k, 2k, 1k 4 hrs 4 days
OVSAHO 500,000 cells 24 hrs 16 hrs 1,000 cells 28 days 10k, 5k, 2k, 1k 4 hrs 4 days
SNU119 200,000 cells 17 hrs 16 hrs 1,000 cells 14 days 10k, 5k, 2k, 1k 4 hrs 4 days
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were different from all other cell lines.  Kuramochi and 
OVCAR4 were not different from each other but were 
different from all other cell lines.  OVCAR5, HeyA8, 
COV362, SNU119, and CAOV3 were not different 
from each other (with the exceptions that OVCAR5 was 
different from COV362, SNU119, and CAOV3, while 
CAOV3 was also different from HeyA8). The time 
required for forming colonies ranged from 7 days for 
HeyA8 cells to 4 weeks for OVSAHO cells (Table 1). 
Therefore, in order to make an accurate comparison, 
the clonogenicity was normalized to the amount of time 
required to form visible colonies and the cell lines were 
ranked accordingly (Table 2). HeyA8 had the greatest 
clonogenicity followed by OVCAR8 while OVSAHO and 
CAOV3 cells had the lowest capacity to form colonies. 
The independent repeats for each cell line are plotted in 
Supplementary Figure 4.
A key feature of cancer progression is EMT. 
Therefore, we characterized the HGSOC cell lines for 
their expression of the epithelial markers E-cadherin 
and claudin and mesenchymal markers vimentin and 
N-cadherin. Total RNA was obtained from the cell lines 
and qRT-PCR was performed for vimentin and E-cadherin. 
Vimentin expression levels were the maximum in HeyA8 
and OVCAR8 cells and were the lowest in SNU119 and 
CAOV3 cells (Figure 5A). OVCAR4 had the highest 
E-cadherin expression and HeyA8 and OVCAR8 had the 
least (Figure 5A). Western blotting was also done to study 
the expression of all the 4 markers. The protein expressions 
of both N-cadherin and vimentin were highest in OVCAR8 
and HeyA8 cells while SNU119 had the maximum 
expression of E-cadherin and claudin (Figure 5B). 
Figure 1: Comparison of the ability of the panel of HGSOC cells to migrate. (A) Transwell migration assay was conducted 
using inserts with 8 μm pores and DMEM with 10% FBS as a chemoattractant. The number of migrated cells per field were imaged 
and counted (mean ± SD; 3 independent experiments). There were significant differences in the means across cell lines (p < 0.0001) as 
described in the results section. (B) Representative images of migrated cells for each cell line.
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The HGSOC cells having high levels of E-cadherin had 
lower expression of vimentin and vice versa. Interestingly, 
CAOV3 had minimal expression of the mesenchymal 
markers and high expression of E-cadherin but did not 
express claudin.
Cell lines are the most commonly used models to 
test new drugs, combination therapies and chemoresistance 
[18, 20, 21]. Since platinum based therapies are the 
standard of care for OC patients, we proceeded to establish 
the IC50 dose for cisplatin in these HGSOC cell lines. 
Having this information would be useful for researchers 
using these cells for chemoresistance experiments 
and for studying combination of different drugs with 
platinum.  COV362 had the highest IC50 dose for cisplatin 
(13.57 μM) and CAOV3 was the most sensitive (IC50 dose 
of 3.14 μM) to cisplatin (Figure 6). 
DISCUSSION
To conduct in vitro experiments to study OC, it is 
essential to use cell lines that accurately represent the 
disease. The TCGA study was an important step towards 
genetic characterization of OC [8] and subsequent 
reports revealed that the most commonly used cell lines 
to model OC in vitro like SKOV3 and A2780 are not the 
best models for HGSOC [6]. While recent reports have 
provided important insights into the genetic characteristics 
of the cell lines that were found to be the best 
representatives of HGSOC [5–7], very limited literature 
is available about their functional characteristics. In order 
to effectively use these cellular models extensively for 
various aspects of OC research, it is essential to study 
their proliferation, clonogenicity, motility, invasiveness, 
drug resistance etc. in vitro and tumorigenicity in vivo. We 
have recently reported the tumorigenic ability of a panel 
of these HGSOC cell lines in mouse xenografts [22] and 
have now extended the study to characterization of their 
functional abilities in vitro, their EMT status as well as 
their resistance to cisplatin. 
The present study is the first to systematically 
compare the in vitro functional characteristics of a set of 
eight HGSOC cell lines. The HGSOC cell lines exhibited 
a wide range of functional activities for each of the 
four assays tested as well as their EMT phenotype and 
cisplatin resistance. Therefore, they accurately represent 
the variability that is characteristic of the disease. It was 
interesting to note that some of the cellular models that 
most closely resemble HGSOC genetically (OVSAHO, 
SNU119 and Kuramochi) were much less potent in the 
functional assays. These in vitro functional assay results 
mirrored their ability to form mouse xenograft tumors 
reported previously [22]. HeyA8 cells, which were used 
Table 2: Compilation of functional assay results
Cell Line
Migration Invasion Proliferation Colony Formation
Mean 
(cell #) SD Rank
Mean 
(cell #) SD Rank
Mean 
(absorbance) SD Rank
Mean 
(colony #) SD Rank
CAOV3 110.2 6.8 5 10.2 1.9 7 1.3 0.2 4 148.2 17.5 8
COV362 106.2 12.5 6 11.4 5.0 6 1.1 0.1 6 164.7 15.8 7
HeyA8 99. 7 21.8 1 257.6 62.1 1 3.0 0.1 1 187.1 17.5 1
Kuramochi 83.5 7.6 7 35.1 2.2 4 0.9 0.1 7 238.9 16.7 3
OVCAR4 145.8 11.9 3 17.8 0.9 5 0.9 0.1 9 228.9 22.1 4
OVCAR5 148.3 17.3 2 268.7 19.1 2 1.5 0.2 2 199.2 15.4 5
OVCAR8 117.1 7.3 4 65.0 10.1 3 1.4 0.2 3 288.8 18.1 2
OVSAHO 10.0 3.0 9 0 8 1.2 0.3 5 43.4 2.0 9
SNU119 21.5 2.7 8 0 8 0.8 0.1 8 162.7 10.7 6
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Figure 2: Evaluation of the ability of the panel of HGSOC cells to invade through matrigel. (A) Transwell invasion assay 
was conducted using growth factor reduced matrigel coated inserts with 8 μm pores. DMEM with 10% FBS served as a chemoattractant. 
The number of invaded cells per field were imaged and counted (mean ± SD; 3 independent experiments). There were significant differences 
in the means across cell lines (p < 0.0001) as described in the results section. (B) Representative images of invaded cells for each cell line.
Figure 3: Capacity of the panel of HGSOC cells to proliferate in vitro. The OC cells were seeded in 96-well plates (2000 cells/well) 
and allowed to grow for 4 days. Thereafter, their proliferation was measured using MTT assay and plotted to compare the growth rate of 
each cell line (mean ± SD; 3 independent experiments). There were significant differences in the means across cell lines (p < 0.0001) as 
described in the results section.
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as a reference for all the functional assays, were found to 
be much more aggressive compared to the HGSOC cells. 
It is important to note that HeyA8 cells have been listed 
as ‘unlikely high-grade serous’ [6]. Similarly SKOV3 
and A2780 are also reported to be more aggressive 
[17, 18, 23]. Therefore, we can conclude that the cell lines 
that genetically resemble HGSOC are less potent in the 
functional assays. This would also agree with the fact 
that the growth rate of HGSOC tumors in patients or in 
patient-derived xenograft models is much slower than that 
observed for HeyA8, SKOV3.ip1 and A2780 xenografts 
[16, 18, 23–25]. These non-HGSOC cells have various 
combinations of mutations in the PI3-kinase, BRAF, 
ARID1A pathways which might help them perform 
better in the functional assays than the HGSOC cells [6]. 
This should be taken into consideration when planning 
experiments to test the effects of specific factors on tumor 
function. 
There was no clear correlation between genetic 
resemblances to HGSOC and the EMT phenotype. All 
the cell line models were found to be relatively sensitive 
to cisplatin, which agreed with the previous report on 
COV362 and CAOV3 [7]. Since most HGSOC patients 
respond well initially to platinum therapy, these cell lines 
would serve as suitable models for studying response to 
platinum treatment and development of chemoresistance. 
In conclusion, these HGSOC cell line models can be 
used as better representatives of the most common form 
Figure 4: Clonogenic potential of the panel of HGSOC cells in vitro. (A) The OC cells were seeded in 6-well plates 
(1000 cells/well) and allowed to grow to form visible colonies. Thereafter, the colonies were fixed, stained, imaged and counted to quantify 
the clonogenicity of these cell lines (mean ± SD; 3 independent experiments). There were significant differences in the means across cell 
lines (p < 0.0001) as described in the results section. (B) Representative images of colonies formed by each cell line.
Oncotarget32817www.impactjournals.com/oncotarget
Figure 5: EMT status of the panel of HGSOC cells. Total RNA was isolated from the OC cells and used for reverse transcription 
followed by qRT-PCR using TaqMan gene expression assays (A) for vimentin and E-cadherin. Relative quantification was done using 
GAPDH as an internal control (mean ± SD; 3 independent experiments). (B) Western blot analysis of N-cadherin, vimentin, E-cadherin 
and claudin expression in the HGSOC cell lines using GAPDH as a loading control. Representative images of 3 independent experiments 
are shown.
Figure 6: Cisplatin resistance of the panel of HGSOC cells. The IC50 values for cispatin were determined in the cell lines by 
treating them with increasing doses of cisplatin for 24 h. This was followed by a 3-day recovery and then MTT assay was conducted to 
measure viability. IC50 was determined using Graph Pad (mean ± SD; 3 independent experiments).
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of the disease. However, there are significant variations 
in their functional abilities, their EMT status as well as 
their sensitivity to cisplatin. Therefore, it is imperative 
that the assay conditions be adapted to the fact that some 
of these are less aggressive in the common functional 
assays tested compared to the OC cell lines that have been 
predominantly used. The standardized conditions reported 
herein would be useful as an appropriate starting point. 
MATERIALS AND METHODS
Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Catalogue # 10-013-CV), MEM vitamins (Catalogue # 
25-020-CI), MEM nonessential amino acids (Catalogue 
# 25-025-CI), Penicillin-Streptomycin (Catalogue # 
30-002-CI) and trypsin (Catalogue # 25-053-CI) were 
purchased from Corning. FBS was purchased from Gibco 
(LifeTechnologies, catalogue # 16000-044). Giemsa stain 
(Catalogue # GS500) and crystal violet (Catalogue # 
C0775) were obtained from Sigma Aldrich. Thiazolyl blue 
tetrazolium bromide was from Acros Organics (Catalogue 
# 298-93-1) and 4% paraformaldehyde solution was 
purchased from Fisher Scientific (NC9245948).
Cell lines
All cell lines were grown in DMEM with 10% 
FBS along with 1% MEM vitamins, MEM nonessential 
amino acids and Penicillin-Streptomycin. CAOV3, 
HeyA8, OVCAR5 and OVCAR8 were obtained from 
Ernst Lengyel, University of Chicago and OVCAR4 
from Joanna Burdette, University of Illinois at Chicago. 
OVSAHO was obtained from the Japanese Collection 
of Research Bioresources and SNU119 was from the 
Korean Cell Line Bank. COV362 (Sigma), and Kuramochi 
(Japanese Collection of Research Bioresources). All cell 
lines used were genetically validated and also confirmed to 
be mycoplasma free using respective services from Idexx 
BioResearch (Columbia, MO). The genetic validation was 
done using the CellCheck 16 (16 Marker STR Profile and 
Inter-species Contamination Test) and mycoplasma testing 
was done using Stat-Myco.
Migration
Transwell migration assays were conducted using 
8 μm pore size inserts (BD, Falcon Cat#353097). OC cells 
were trypsinized, recovered for 30 min at 37°C in the CO2 
incubator (5% CO2) and then seeded in the upper chamber 
in 500 μl of serum free DMEM and allowed to migrate 
at 37°C. The numbers of cells seeded per insert and 
migration times are included in Table 1. DMEM with 10% 
FBS was used as a chemoattractant in the lower chamber. 
At the endpoint, cells were fixed in 4% paraformaldehyde 
for 30 min at room temperature, stained with Giemsa for 
3 h followed by rinsing with distilled water and thorough 
wiping of the inside surface of the transwell membrane to 
remove any cells that have not migrated. The inserts were 
air-dried and imaged (5 fields/insert) using an EVOS FL 
Auto microscope (Life Technologies). Since the number 
of cells and the migration times varied between cell lines, 
the results were normalized to the number of cells seeded 
and the time of migration. Since the majority of cells were 
seeded at 200,000 cells/insert the cell number adjustment 
factor (N) was determined as follows:
N = 200,000/number of cells seeded for the cell line
Similarly, the baseline migration time was set at 
8 h and the migration time adjustment factor (T) was 
calculated as follows:
T = 8/migration time for the cell line
The final adjusted cell count took into account the 
cell number adjustment factor (N) and the migration time 
adjustment factor (T) and was determined by:
Adjusted cell count = average number of cells per 
field × N × T
Invasion 
Cellular invasion through the extracellular matrix 
proteins was assayed using growth factor reduced matrigel 
coated transwell inserts (8 μm pore size, BD Falcon Cat# 
354483) in 24-well plates. OC cells were trypsinized, 
recovered for 30 min at 37°C in the CO2 incubator and then 
seeded in the transwell insert in 500 µl serum-free DMEM. 
The number of cells seeded per insert are included in Table 
1. DMEM with 10% FBS served as a chemoattractant in 
the lower chamber.  Cells were allowed to invade for 16 
h and then were fixed with 4% paraformaldehyde. The 
OC cells that had invaded were stained with Giemsa for 
3 h followed by rinsing with distilled water and thorough 
wiping of the inside surface of the transwell membrane to 
remove any cells that have not migrated. The inserts were 
air-dried and imaged (5 fields/insert) using an EVOS FL 
Auto microscope (Life Technologies). The number of cells 
seeded per insert varied between cell lines but the invasion 
time was constant. Therefore, the normalization method 
used for migration was modified to exclude the time factor 
as follows:
Adjusted cell count = average number of cells per 
field × N 
Where N = 200,000/number of cells seeded for the 
cell line.
Proliferation
OC cells were seeded in 96-well plates in 8 
replicates and allowed to grow for 5 days. To identify 
the optimal number of cells for comparison between 
cell lines, 1000, 2000, 5000 and 10000 cells of each cell 
line were seeded per well. On the fourth day MTT (3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
Assay was conducted to measure proliferation of the OC 
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cells. 20 μl of MTT solution (5 mg/ml in sterile PBS) 
was added per well, mixed and incubated at 37°C. The 
incubation times for the OC cell lines are listed in Table 1. 
Thereafter, the colored product (formazan) was solubilized 
in DMSO and the absorbance measured at 560 nm and 
adjusted for background absorbance at 670 nm using a 
SynergyH1 plate reader (BioTek).
Colony formation
OC cells were seeded in 6-well plates (1000 cells/
well, 6 replicates) and allowed to form colonies. Medium 
was changed every fifth day. Once visible colonies were 
formed (cell line specific colony formation times are listed 
in Table 1), they were fixed with 4% paraformaldehyde 
and stained with 0.005% crystal violet and were imaged 
using a Syngene G:Box imaging system and the number 
of colonies/well were counted. The time required to form 
visible colonies varied between cell lines and therefore the 
colony counts were normalized for the time of growth. 
The baseline colony formation time was set at 14 days and 
the time adjustment factor (T) was calculated as follows:
T = 14/colony formation time for the cell line
Thereafter, the final adjusted colony count was 
determined as follows:
Adjusted colony count = Average number of 
colonies × T
Cisplatin IC50
OC cells were plated at 2000 cells per well in a 96-
well plate and 48 h after plating, cells were treated with 
increasing concentrations of cisplatin for 24 h. Thereafter, 
medium was changed and cells were allowed to recover 
for 72 h followed by MTT assay. IC50 was determined 
using Graph Pad Prism.
Real time polymerase chain reaction
Quantitative real time polymerase chain (qRT-PCR) 
reaction was done for E-cadherin and vimentin using 
TaqMan gene expression assays as described previously 
[15]. Briefly, RNA was isolated from the cells using 
miRNeasy Kit (Qiagen Catalogue # 217004) and 1 μg 
RNA was used for reverse transcription using Applied 
Biosystems High Capacity Reverse Transcription Kit 
(Catalogue # 4368813). The relative E-cadherin and 
vimentin mRNA expression levels were determined using 
TaqMan gene expression assays (Applied Biosystems 
catalogue # Hs01023894_m1 and Hs00185584_m1 
respectively). GAPDH was used as an internal control. 
qPCR was done using Roche LightCycler 96 system and 
the RT was done using a Veriti 96-well thermal cycler 
(Applied Biosystems).
Western blotting
Western blotting was done as described previously 
[15]. Briefly, cells were lysed in ice-cold RIPA buffer and 
proteins were resolved using 4–20% gradient sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
followed by transfer to nitrocellulose membrane. Anti 
N-cadherin, E-cadherin, vimentin and claudin antibodies 
(Cell Signaling EMT Antibody Sampler Kit, Catalogue 
# 9782S) were used to probe for the respective proteins 
and detected using a horseradish peroxidase-linked anti-
rabbit IgG secondary antibody (Cell Signaling, Cat#7074). 
Membranes were stripped and re-probed with HRP linked 
anti-GAPDH antibody (Sigma catalogue # G9295).
Cell size measurements
Cell diameter was analyzed using the Z2 coulter 
Particle Count and Size Analyzer (Beckman Coulter, 
Miami, FL) using a 100 μm aperture size.  Briefly, cells 
were diluted 1:10 in diluent (Isoton II) and 0.5 ml was 
loaded into the counter.  All particles over 12 um were 
counted and measured. Between sample readings, the 
counter was flushed with the diluent.  
Statistics
ANOVA was used to compare mean migration, 
invasion, proliferation, and colony formation by cell line. 
The p-value from the overall F-test is reported. Tukey’s 
method was used for pair-wise comparisons. The overall 
error rate per outcome was controlled at 5%.
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